SavedAdd your journal

Journals / Şişli Etfal Hastanesi Tıp Bülteni / 2021 / Cilt: 55 - Sayı: 1

A Comparative Analysis of Once-daily and Twice-daily Formulation of Tacrolimus in De Novo Kidney Transplant Recipients

Murat Ferhat FERHATOGLU
Abdulcabbar KARTAL
Taner KİVİLCİM
Ali Ilker FİLİZ
Gursel YİLDİZ
Alp GURKAN
Pages
62–67
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

However, a higher daily dosage of TAC-OD is needed to achieve similar blood concentrations in the early postoperative period.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: We aimed to compare the once-daily and twice-daily formulation of tacrolimus concerning the efficiency and effects on graft function in de novo kidney transplant patients.
📊
Key Findings & Data:Methods: Twenty once-daily (TAC-OD) and twenty twice-daily (TAC-BID) tacrolimus administrated de novo kidney recipients who had received initial immunosuppressive therapy according to protocols at our institution (0.2 mg/kg of tacrolimus combined with 1000 milligrams of steroid taper plus 720 mg of mycophenolate and with 2.5mg/kg anti-thymocyte globulin) assessed concerning demographics, drug doses and blood concentration, and graft function.
💡
Conclusion & Impact:However, a higher daily dosage of TAC-OD is needed to achieve similar blood concentrations in the early postoperative period.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Objectives: We aimed to compare the once-daily and twice-daily formulation of tacrolimus concerning the efficiency and effects on graft function in de novo kidney transplant patients. Methods: Twenty once-daily (TAC-OD) and twenty twice-daily (TAC-BID) tacrolimus administrated de novo kidney recipients who had received initial immunosuppressive therapy according to protocols at our institution (0.2 mg/kg of tacrolimus combined with 1000 milligrams of steroid taper plus 720 mg of mycophenolate and with 2.5mg/kg anti-thymocyte globulin) assessed concerning demographics, drug doses and blood concentration, and graft function. Results: The mean tacrolimus blood concentration measurements were higher in the TAC-OD group in the first sixty days after transplantation, and the TAC-OD group showed more blood concentration overshoots/fluctuations in the first 30 days of the treat- ment. The initial drug dose was significantly higher in the TAC-OD group than the TAC-BID group (p=0.04). There was no meaning- ful difference among groups according to graft function (creatinine measurements) (p>0.05). Conclusion: Between de novo kidney recipients, the new TAC-OD formulation presents a similar short-term efficacy profile as TAC- BID. However, a higher daily dosage of TAC-OD is needed to achieve similar blood concentrations in the early postoperative period.

🔖

Cite This Article

FERHATOGLU, M. F., KARTAL, A., KİVİLCİM, T., FİLİZ, A. I., YİLDİZ, G., GURKAN, A. (2021). A Comparative Analysis of Once-daily and Twice-daily Formulation of Tacrolimus in De Novo Kidney Transplant Recipients. Şişli Etfal Hastanesi Tıp Bülteni, Cilt: 55 - Sayı: 1, 62–67. https://ajindex.com/articles/402851

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Banas B, Krämer BK, Krüger B, Kamar N, Undre N. Long-term kid- ney transplant outcomes: role of prolonged-release tacrolimus. Transplant Proc 2020;52:102–10
  2. Danguilan RA, Lamban A, Pamugas GEP. Pilot study comparing the efficacy, safety, convertibility, and tacrolimus trough lev - els of twice-daily tacrolimus (prograf ) to once-daily tacrolimus (advagraf ) among standard-risk kidney transplant patients at the national kidney and transplant institute. Transplant Proc 2019;51:2615–9
  3. Sukkha S, Suansanae T, Iamrahong P, Wiwattanathum P. Trough level and tacrolimus variability of early converted once-daily tac- rolimus: 1-Year Follow-up Study. Transplant Proc 2020;52:775–9
  4. First MR. First clinical experience with the new once-daily formu- lation of tacrolimus. Ther Drug Monit 2008;30:159–66
  5. First MR, Fitzsimmons WE. Modified release tacrolimus. Yonsei Med J 2004;45:1127–31
  6. Kamińska D, Poznański P, Kuriata-Kordek M, Zielińska D, Mazanowska O, Kościelska-et al. Conversion from a twice-daily to a once-daily tacrolimus formulation in kidney transplant recipi- ents. Transplant Proc 2020;52:2288–93
  7. Fellström B, Holmdahl J, Sundvall N, Cockburn E, Kilany S, Wen- nberg L. Adherence of renal transplant recipients to once-daily, prolonged-release and twice-daily, immediate-release tacroli- mus-based regimens in a real-life setting in Sweden. Transplant Proc 2018;50:3275–82
  8. Rathi M, Rajkumar V, Rao N, Sharma A, Kumar S, Ramachandran R, et al. Conversion from tacrolimus to cyclosporine in patients with new-onset diabetes after renal transplant: an open-label random- ized prospective pilot study. Transplant Proc 2015;47:1158–61
  9. Saengram W, Vadcharavivad S, Poolsup N, Chancharoenthana W. Extended release versus immediate release tacrolimus in kidney transplant recipients: a systematic review and meta-analysis. Eur J Clin Pharmacol 2018;74:1249–60
  10. Liu Y, Liu H, Shen Y, Chen Y, Cheng Y. Delayed initiation of tacro- limus is safe and effective in renal transplant recipients with de - layed and slow graft function. Transplant Proc 2018;50:2368–70
  11. Kukla U, Cholewa H, Chronowska J, Goc T, Lieber E, Kolonko A, et al. Effect of the second warm ischemia time and its components on early and long-term kidney graft function. Transplant Proc 2016;48:1365–9
  12. Davari HR, Malek-Hossini SA, Salahi H, Bahador A, Rais-Jalali GA, Behzadi S, et al. Sequential anastomosis of accessory renal artery to external iliac artery in the management of renal